argenx SE (EBR: ARGX)
Belgium
· Delayed Price · Currency is EUR
637.80
-3.20 (-0.50%)
Jan 17, 2025, 5:36 PM CET
argenx SE Revenue
argenx SE had revenue of $588.88M USD in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
22.06
Revenue / Employee
$1.66M
Employees
1,148
Market Cap
38.30B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UCB SA | 5.45B |
Fagron NV | 820.76M |
Nyxoah | 5.08M |
Ion Beam Applications | 465.75M |
Onward Medical | -188.00K |
Hyloris Pharmaceuticals | 6.94M |
Sequana Medical NV | 433.50K |
Biocartis Group NV | 60.82M |
argenx SE News
- 3 days ago - Argenx cut to Sell at Deutsche Bank on valuation - Seeking Alpha
- 8 days ago - Immunology company argenx estimates higher product net sales from last year - Seeking Alpha
- 8 days ago - argenx SE (ARGX) Announces Preliminary 2024 Financial Results and Strategic Priorities for 2025 - GuruFocus
- 8 days ago - argenx Highlights 2025 Strategic Priorities - GlobeNewsWire
- 15 days ago - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years - Benzinga
- 25 days ago - argenx SE (ARGX) Gains Approval for VYVDURA in Japan for CIDP Treatment - GuruFocus
- 25 days ago - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire